



HAL
open science

Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir

Tuija H. Nieminen, Nora M. Hagelberg, Teijo I. Saari, Mikko Neuvonen, Pertti J. Neuvonen, Kari Laine, Klaus T. Olkkola

► To cite this version:

Tuija H. Nieminen, Nora M. Hagelberg, Teijo I. Saari, Mikko Neuvonen, Pertti J. Neuvonen, et al.. Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. *European Journal of Clinical Pharmacology*, 2010, 66 (10), pp.977-985. 10.1007/s00228-010-0879-1 . hal-00614173

HAL Id: hal-00614173

<https://hal.science/hal-00614173>

Submitted on 10 Aug 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir



Journal:	<i>European Journal of Clinical Pharmacology</i>
Manuscript ID:	EJCP-2010-0202.R1
Type of submission:	Original
Date Submitted by the Author:	20-Jul-2010
Complete List of Authors:	<p>Nieminen, Tuija; Turku University Hospital and Turku University, Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine</p> <p>Hagelberg, Nora; Turku University Hospital, Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine</p> <p>Saari, Teijo; Turku University Hospital, Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine</p> <p>Neuvonen, Mikko; University of Helsinki and Helsinki University Central Hospital, Department of Clinical Pharmacology</p> <p>Neuvonen, Pertti; University of Helsinki and Helsinki University Central Hospital, Department of Clinical Pharmacology</p> <p>Laine, Kari; Turku University, Department of Pharmacology, Drug Development & Therapeutics</p> <p>Olkkola, Klaus; Turku University Hospital and Turku University, Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine</p>

1
2
3 **Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or**
4
5 **lopinavir/ritonavir**
6
7

8
9
10 **Authors:** Tuija H Nieminen, M.D.¹, Nora M Hagelberg, M.D., Ph.D.¹, Teijo I Saari, M.D., Ph.D.¹, Mikko
11 Neuvonen, M.Sc.², Pertti J Neuvonen, M.D., Ph.D.², Kari Laine, M.D., Ph.D.³ Klaus T Olkkola, M.D., Ph.D.¹
12
13

14 **Affiliations:**

15
16 ¹Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University
17 Hospital and University of Turku, Turku, Finland.
18

19
20 ²Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital,
21 Helsinki, Finland.
22

23
24 ³Department of Pharmacology, Drug Development & Therapeutics, University of Turku, Turku, Finland.
25
26

27 **Corresponding author:**

28
29 Tuija H Nieminen, Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine,
30 Turku University Hospital, P.O. Box 52 (Kiinamylynkatu 4–8), FI–20521 Turku, Finland;
31
32 Tel. +358-2-313 0000 (work); Fax +358-2-313 3960 E-mail: tuija.nieminen@utu.fi
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Purpose: This study was aimed to investigate the effect of antivirals ritonavir and lopinavir/ritonavir on the pharmacokinetics and pharmacodynamics of oral oxycodone, a widely used opioid receptor agonist used in the treatment of moderate to severe pain.

Methods: A randomized crossover study design with 3 phases at intervals of 4 weeks was conducted in 12 healthy volunteers. Ritonavir 300 mg, lopinavir/ritonavir 400/100 mg or placebo b.i.d. for 4 days was given to the subjects. On day 3, 10 mg oxycodone hydrochloride was administered orally. Plasma concentrations of oxycodone, noroxycodone, oxymorphone and noroxymorphone were determined for 48 h. Pharmacokinetic parameters were calculated with standard noncompartmental methods. Behavioural effects and experimental cold pain analgesia were assessed for 12 h. ANOVA for repeated measures was used for statistical analysis.

Results: Ritonavir and lopinavir/ritonavir increased the area under the plasma concentration–time curve of oral oxycodone by 3.0- (range 1.9- to 4.3-fold; $P<0.001$) and 2.6-fold (range 1.9- to 3.3-fold; $P<0.001$). The mean (\pm SD) elimination half-life prolonged after ritonavir and lopinavir/ritonavir from 3.6 ± 0.6 to 5.6 ± 0.9 h ($P<0.001$) and 5.7 ± 0.9 h ($P<0.001$), respectively. Both ritonavir ($P<0.001$) and lopinavir/ritonavir ($P<0.05$) increased the self-reported drug effect of oxycodone.

Conclusions: Ritonavir and lopinavir/ritonavir greatly increase the plasma concentrations of oral oxycodone in healthy volunteers and enhance its effect. When oxycodone is used clinically in patients during ritonavir and lopinavir/ritonavir treatment, reductions in oxycodone dose may be needed to avoid opioid-related adverse-effects.

Keywords: Oxycodone, Ritonavir, Lopinavir/ritonavir, Interaction, Pharmacokinetics, Pharmacodynamics

INTRODUCTION

Pain is one of the most frequently reported symptoms associated with human immunodeficiency virus (HIV) infection. It has been estimated that in the developed world, depending on the stage of disease and study settings, 30–80% of people living with HIV/AIDS are affected with pain [1, 2]. Pain experienced by HIV patients can be acute or chronic, and it is usually multifactorial in origin. HIV-associated pain can be due to e.g. HIV itself, antiretroviral treatment, opportunistic infections, HIV-associated cancers, rheumatic conditions or peripheral polyneuropathy [3-5]. Unfortunately, these painful conditions are often under-recognised and -treated.

Oxycodone is a semi-synthetic opioid agonist, which is effective in treating acute, cancer-related and chronic pain [6, 7]. It is metabolized mainly via oxidative, but also via reductive pathways with only 10–14% being excreted in unchanged or conjugated forms in urine [8]. Oxycodone is principally a cytochrome P450 3A4/5 substrate, which makes it prone to the interactions with CYP3A inducers and inhibitors [9]. The main oxidative pathway includes N-demethylation to noroxycodone by CYP3A4/5 and further to noroxymorphone by CYP2D6 [9]. Approximately 11% of oxycodone is O-demethylated to oxymorphone by CYP2D6, which is further transformed to noroxymorphone by CYP3A4/5 and CYP2D6 [9]. Animal studies have given controversial results about the role of P-glycoprotein in the transport of oxycodone via blood-brain barrier (BBB) [10, 11]. However, the higher concentrations of oxycodone in rat and sheep brain tissue compared to plasma concentrations suggest that the influx protein is much more active than P-glycoprotein, which acts as an efflux protein limiting the concentrations of oxycodone in brain [12-14].

HIV protease inhibitors, such as ritonavir and lopinavir inflict the HIV-specific aspartic protease enzyme on processing the *gag* and *gag-pol* polyprotein precursor, which leads to the production of immature, non-infectious viral particles [15]. Ritonavir is a potent CYP3A, CYP2D6 and P-glycoprotein inhibitor [16-18]. It has been described to induce CYP1A2, CYP2B6, CYP2C9 and CYP2C19 [19, 20]. Difficult dosing regimens, the development of resistance and adverse effects have restricted the use of ritonavir as an independent part of HIV treatment [21]. Lopinavir/ritonavir is a combination preparation, where lopinavir is

1
2
3 combined with low-dose ritonavir to enhance its low bioavailability by favourable CYP3A inhibition [22].
4

5 Lopinavir/ritonavir has become a well-tolerated, effective and preferred protease inhibitor in the treatment of
6
7 HIV. It is a substrate and inhibitor of CYP3A4 and to a lesser extent CYP2D6, and an inducer of CYP1A2,
8
9 2B6, 2C9 and 2C19 [23, 24] which makes it prone to cytochrome P450-mediated interactions.
10
11

12
13
14 In previous studies it has been shown, that CYP3A inhibitors voriconazole [25], itraconazole [26] and
15
16 telithromycin [27] increased the concentrations of oxycodone and oxymorphone, but only minor changes
17
18 have been observed in the pharmacological action of oxycodone following single doses in healthy
19
20 volunteers. As HIV patients are often affected with moderate to severe pain, there is an obvious need for the
21
22 concomitant use of antivirals and strong opioids, such as oxycodone. The aim of this study was to investigate
23
24 the effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics and effects of oxycodone in healthy
25
26 volunteers.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Participants

The study protocol was approved by the Ethics Committee of the Hospital District of Southwest Finland and by the Finnish National Agency for Medicines and was and was thereby reported to the EudraCT clinical trial register. In view of our previous studies, it was calculated, that 10 subjects would be required to detect a 30% difference in the area under the oxycodone concentration–time curves ($AUC_{0-\infty}$) at a level of significance $P = 0.05$ and power of 80% [25-27]. To allow a drop-out rate of 20%, we decided to recruit 12 subjects. Twelve healthy volunteers, four women and eight men (age 18–26 years; weight 52–84 kg) were studied according to the revised Declaration of Helsinki. Informed consent was obtained from all subjects before study screening. All participants were ascertained to be healthy by means of medical history and clinical examination, and they were tested for routine laboratory tests. Urine screens for drugs with abuse risk were negative and a 12–lead electrocardiogram (ECG) within normal limits. Pregnancy tests for women were negative. None of the participants were receiving any continuous medication including hormonal contraception and all were non-smokers. Women in need of contraception were instructed to use non-hormonal methods during the study.

Finnish translation of Abuse Questions [28] was used to assess risk for drug abuse. The consumption of any product with potential CYP3A effect such as herbal remedies or grapefruit juice was forbidden for 4 weeks and all other drugs for 2 weeks before and during the study. Consumption of coffee, tee, alcohol and cola drinks were not allowed in the study facility during the study days. Genotyping for CYP2D6 was conducted by a two-step multiplex primer extension method [29]. This method enables the detection of 11 most relevant polymorphic positions, the definition of whole-gene deletion, duplication and the allele combination in case of gene duplication.

Study design and drug dosing

1
2
3 We used a randomized, crossover study design with three phases at intervals of four weeks. During each
4
5 phase, the volunteers were given 4 capsules or tablets b.i.d. at 7 a.m. and 7 p.m. for 4 days. The capsules and
6
7 tablets were packed into sealed coded envelopes which contained either:

- 10 1. Two lopinavir/ritonavir 200 mg/50 mg tablets (Kaletra[®], Abbott Laboratories Ltd, Queenborough,
11 UK) and two placebo capsules
- 12 2. Three ritonavir 100 mg capsules (Norvir[®], Abbott Laboratories Ltd, Queenborough, UK) and one
13 placebo capsule
- 14 3. Four placebo capsules.

15
16
17
18
19
20 An oral dose of 10 mg oxycodone hydrochloride (Oxynorm[®] 10 mg capsule, Mundipharma, Bard
21
22 Pharmaceuticals Ltd, Cambridge, UK) was administered on day 3 at 8 a.m. with 150 ml warm water. The
23
24 participants arrived at the study facility one hour before oxycodone administration and were under
25
26 supervision 12 hours after the dosing.

27
28
29
30
31 The volunteers fasted for 8 h before oxycodone hydrochloride administration and received a standard meal 4
32
33 and 8 h after dosing. Drinking was allowed only during the meals. Adherence to the pre-treatment
34
35 medication schedule was ensured with mobile phone text messages, which the volunteers sent to the
36
37 investigator after taking each dose of pre-treatment taken outside the study facility.

38 39 40 41 42 **Sampling and determination of drug concentrations**

43
44 In the study facility, a cubital vein was cannulated for blood sampling. The samples (10 ml each) were
45
46 collected into EDTA containing tubes before and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 h after the oxycodone
47
48 hydrochloride dose. Plasma was separated within 30 min and stored at -70°C until analysis.

49
50
51
52
53 Plasma concentrations of oxycodone, noroxycodone, oxymorphone and noroxymorphone were analyzed
54
55 with the liquid chromatography–tandem mass spectrometric (LC–MS/MS) method as described earlier [30].
56
57 The lower limits of quantification (LLQ) were 0.1 ng/mL for oxycodone and oxymorphone, and 0.25 ng/mL
58
59 for noroxycodone and noroxymorphone. The interday coefficient of variation was less than 6% for parent
60
oxycodone and less than 13% for the metabolites at relevant plasma concentrations.

1
2
3
4
5 The concentrations of ritonavir and lopinavir just before and 2 h after the administration of the dose of
6 pretreatment on the day 3 were determined with a LC–MS/MS method [31]. Saquinavir was used as internal
7 standard. The LLQ was 0.1 µg/ml for ritonavir and 0.4 µg/ml for lopinavir. The interday CVs were < 5.4%
8 and < 7.0% for ritonavir and lopinavir, respectively, at relevant concentrations (n=3).
9
10
11
12
13

16 **Pharmacokinetic analysis**

17
18 The pharmacokinetics of oxycodone and its metabolites were determined by standard noncompartmental
19 methods using a pharmacokinetic program WinNonlin (version 4.1, Pharsight Corporation, Mountain View,
20 CA, USA). The peak plasma concentrations (C_{\max}) and the corresponding C_{\max} times (t_{\max}) were observed
21 directly from the data. The elimination rate constant (k_e) was determined by log-linear regression. The
22 elimination half-life $t_{1/2}$ was calculated from $\ln 2/k_e$. The areas under the oxycodone, noroxycodone,
23 oxymorphone and noroxymorphone concentration–time curves ($AUC_{0-\infty}$) were calculated by trapezoidal rule
24 with extrapolation to infinity. Whenever k_e could not be estimated because of low plasma concentrations of
25 the metabolite, AUC_{0-48} was used instead of $AUC_{0-\infty}$. The metabolite-to-parent drug AUC ratios
26 (AUC_m/AUC_p) were calculated to compare the relative abundance of each metabolite.
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Analysis of pharmacological effects**

44 ***Behavioral effects***

45
46 The behavioural measures were performed before and at 1, 2, 3, 4, 5, 6, 8, 10 and 12 h after oxycodone as
47 described earlier [32]. Subjective assessment of drowsiness, deterioration of performance, self-reported drug-
48 effect, pleasantness and nausea or vomiting was quantified using visual analog scales (VAS) and scored 0–
49 100. Attributes assessed included alert/drowsy, good/poor performance, no/strong drug effect,
50 unpleasant/pleasant feeling and no/extreme nausea or vomiting [33]. Maddox wing test was used to estimate
51 the central coordination of extraocular muscles [34]; digit symbol substitution test (DSST) to estimate the
52 central processing of sensory information [35] and Cogan's pupillometry to measure pupil diameter [36]. All
53 reported and observed adverse effects were recorded.
54
55
56
57
58
59
60

Experimental pain

The analgesic effect was studied in an experimental cold pressor test, which is sensitive to opioid effects [37]. The subjects placed their left hand up to the wrist into the ice water bath (temperature 0–2°C) for one minute and reported the first sensation of pain (cold pain threshold, CPT), which was measured in seconds with a stopwatch. The intensity of cold pain at 60 s (CPI) was assessed using numerical rating scale (NRS 0–100). The area under the drug effect–time curve (AUEC_{0–12}) from 0 to 12 hours was calculated with linear trapezoidal rule based on the observations by the use of the WinNonlin (version 4.1, Pharsight Corporation, Mountain View, CA, USA) software for all effect variables.

Statistics

The results are expressed as mean \pm SD, except for t_{\max} , where medians with minimum and maximum values are reported. In figures, for clarity, mean \pm SEM are given. Descriptive and comparative statistics were calculated with use of SYSTAT for Windows (version 10.2; Systat software, Richmond, CA, USA). The pharmacokinetic and pharmacodynamic variables were compared with the use of analysis of variance for repeated measures and a posteriori testing was performed with Tukey's test. Pharmacokinetic data was logarithmically transformed before statistical comparisons. Analysis of variance was used to determine the contributions of treatment, CYP2D6-genotype, gender, phase and sequence on overall variance. The t_{\max} was analyzed by Friedman's test and Wilcoxon signed rank test was used for pair wise comparisons. *P* was considered significant at the level of <0.05 . We also calculated geometric mean ratios with 90% confidence intervals (CI) for the pharmacokinetic parameters. Bioequivalence (i.e., the lack of an interaction) was concluded, if the 90% CI of the geometric mean ratios (coadministration/oxycodone alone) were within the acceptance limit of 0.8 to 1.25.

RESULTS

All subjects completed the study.

Pharmacokinetic results

The pharmacokinetic results are presented in Figure 1 and Table 1. During the ritonavir and lopinavir phases, all of the calculated pharmacokinetic parameters for oxycodone were outside the bioequivalence acceptance limits (Table 1). Compared with placebo, ritonavir and lopinavir/ritonavir increased the oxycodone $AUC_{0-\infty}$ (geometric mean ratio) by 3.0-fold (90% CI 2.6, 3.4; $P<0.001$) and 2.6-fold (90% CI 2.3, 2.9; $P<0.001$), respectively. Ritonavir increased the geometric mean ratio of oxycodone C_{max} by 1.7-fold (90% CI 1.5, 2.0; $P<0.001$) and prolonged its elimination half-life from 3.6 ± 0.6 h to 5.6 ± 0.9 h ($P<0.001$).

Lopinavir/ritonavir increased the geometric mean ratio of oxycodone C_{max} by 1.4-fold (90% CI 1.2, 1.7; $P<0.05$) and prolonged its elimination half-life to 5.7 ± 0.9 hours ($P<0.001$). Gender had no significant influence on the pharmacokinetic parameters of oxycodone.

Both ritonavir and lopinavir/ritonavir decreased the geometric mean ratio for noroxycodone AUC_{0-48} to 0.49 (90%CI 0.43, 0.58, $P<0.001$) and 0.44 (90%CI 0.38, 0.50; $P<0.001$), respectively. Ritonavir alone had no effect on oxymorphone but lopinavir/ritonavir increased geometric mean ratio for oxymorphone AUC_{0-48} by 2.7-fold (90%CI 2.0, 3.8; $P<0.05$). The geometric mean ratio for noroxymorphone AUC_{0-48} was 0.19 (90%CI 0.15, 0.24; $P<0.01$) after ritonavir and 0.24 (90%CI 0.16, 0.35; $P<0.01$) after lopinavir/ritonavir, respectively. Four subjects during ritonavir phase and three subjects during lopinavir/ritonavir phase had no detectable concentrations of noroxymorphone during the study period 0–48 hours.

Nine volunteers were classified as extensive metabolizers (EM). Three of them were homozygous for CYP2D6*1 allele and the rest of the genotypes were CYP2D6*1/4 ($n = 3$), CYP2D6*1/5 ($n = 2$) and CYP2D6*1/41 ($n=1$). Furthermore, there were two subjects with CYP2D6*1/1 x 2 genotype classified as ultrarapid metabolizer (UM) and one CYP2D6*10/*41 classified as intermediate metabolizer (IM). The IMs

1
2
3 appeared to have lower oxymorphone AUC values than most of the extensive metabolizers during all phases
4
5 (data not shown).
6
7
8

9
10 After pre-treatment with ritonavir, plasma ritonavir concentrations (mean \pm SD) measured $\frac{1}{2}$ and 3 hours
11 after the morning dose on day 3, were 3.2 ± 1.6 $\mu\text{g/ml}$ and 8.7 ± 2.6 $\mu\text{g/ml}$. After lopinavir/ritonavir pre-
12 treatment, the corresponding plasma lopinavir concentrations were 9.0 ± 2.0 $\mu\text{g/ml}$ and 11.3 ± 2.9 $\mu\text{g/ml}$ and
13 ritonavir concentrations 0.5 ± 0.3 $\mu\text{g/ml}$ and 1.0 ± 0.5 $\mu\text{g/ml}$, respectively. All volunteers had measurable
14 values of ritonavir and ritonavir/lopinavir before the morning dose during active phases indicating
15 compliance to the dosing schedule.
16
17
18
19
20
21
22
23
24

25 **Pharmacodynamic results**

26
27 Results from behavioral and analgesic tests are shown in Fig. 2. The self-reported drug effect AUEC_{0-12}
28 increased significantly after ritonavir and lopinavir/ritonavir ($P < 0.001$ and < 0.05). Ritonavir increased also
29 nausea or vomiting as measured by VAS ($P < 0.01$), but no other statistically significant differences were
30 observed in the pharmacological response to oxycodone.
31
32
33
34
35
36
37

38 The adverse effects reported are presented in Table 2. All three volunteers with vomiting were treated with 2
39 mg intravenous tropisetron 4, 8 or 12 h after oxycodone.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

This study convincingly demonstrates that short-term administration of ritonavir and lopinavir/ritonavir strongly inhibits the CYP3A-mediated N-demethylation of oxycodone, as reflected by an approximately 2–3-fold increase in oxycodone $AUC_{0-\infty}$ and decrease in noroxycodone AUC_{0-48} . When oxycodone was administered together with ritonavir or lopinavir/ritonavir, the mean concentration of oxycodone was still higher at 8 h than the C_{max} during the control phase. These pharmacokinetic changes were accompanied by enhanced self-reported drug-effect after both antiviral treatments.

Ritonavir has been shown to be a strong inhibitor of CYP3A both *in vitro* [38, 39] and *in vivo* [16, 18, 40, 41]. In the present study ritonavir caused a 3-fold mean increase of oxycodone $AUC_{0-\infty}$, which is somewhat smaller than that observed after the azole antimycotic voriconazole (3.6-fold increase in oxycodone $AUC_{0-\infty}$), but bigger than that observed for itraconazole (2.4-fold increase) and telithromycin (1.8-fold increase) [25-27]. It can be speculated, although it seems doubtful, that the interaction between oxycodone and ritonavir would have been stronger, if a larger ritonavir dose would have been used as recommended by the manufacturer. However, because we wanted to minimize possible adverse effects in healthy volunteers, 300 mg b.i.d. was used and the treatment lasted only four days. This could lead to bias, as the steady-state was not reached [21]. Ritonavir has been reported to cause an enzyme induction after approximately 2 weeks administration, which can diminish the inhibitory effects [42, 43].

Interestingly, lopinavir/ritonavir resulted in an almost equal alteration in oxycodone pharmacokinetics as compared to ritonavir. The clinically used maintenance dose of ritonavir is 600 mg b.i.d., which is recommended to be attained during 2 weeks to avoid adverse effects. During the 4-day pre-treatment our volunteers were given 300 mg of ritonavir b.i.d., which is three times higher than the dose of ritonavir during lopinavir/ritonavir phase. Still, the pharmacokinetics of oxycodone was very similar whether it was given together with ritonavir or lopinavir/ritonavir. A plausible explanation for the observed pharmacokinetic changes is the additional inhibitory effect by lopinavir. Lopinavir is a less potent inhibitor of CYP3A *in vitro* than ritonavir, but it might nonetheless contribute to net CYP3A inhibition *in vivo* during the treatment with

1
2
3 the combination of lopinavir and ritonavir. The dose-response curve for CYP3A inhibition by ritonavir can
4
5 be so flat *in vivo* that despite a 3-fold dose reduction, it causes a maximal inhibition of CYP3A when
6
7 combined with a 4-fold higher dose of lopinavir [44].
8
9

10
11 Ritonavir inhibits CYP2D6 *in vitro*, but to a lesser extent than it inhibits CYP3A [44, 45]. In the present
12
13 study, oxycodone concentrations were increased during both antiviral phases indicating the increased
14
15 significance of compensatory oxycodone metabolic route via CYP2D6 during CYP3A inhibition. In a
16
17 previous study, coadministration of oxycodone and telithromycin, an inhibitor of CYP3A and CYP2D6,
18
19 shifted the metabolism of oxycodone towards the CYP2D6-mediated route increasing oxycodone
20
21 concentrations [27]. After lopinavir/ritonavir, the geometric mean ratio for oxycodone AUC was
22
23 increased by 2.7-fold. Earlier studies have reported CYP2D6 inhibition during lopinavir/ritonavir [17, 24].
24
25
26 The inhibition was not strong enough to totally hinder the compensation via CYP2D6-mediated route after
27
28 CYP3A inhibition. The formation of oxycodone has recently been shown to be dependent on CYP2D6
29
30 genotype [46]. In our study with only 12 healthy volunteers, there were 9 extensive, one intermediate, two
31
32 ultrarapid but no poor metabolizers. In the present small-scale study these genotypes were not associated
33
34 with changes in pharmacokinetic parameters of oxycodone or its metabolites.
35
36
37
38
39

40 The self-reported drug effect of oxycodone was significantly increased by both ritonavir and
41
42 lopinavir/ritonavir. As well as oxycodone, also ritonavir was involved in the side-effects because
43
44 approximately 25% of ritonavir users typically report nausea or vomiting [21]. Contrary to our previous
45
46 studies, oxycodone reduced pain in the cold pressor test only in some subjects. As only a single dose of
47
48 oxycodone was used in the current study in order to minimize the exposure of healthy volunteers to opioids,
49
50 drug effect remained smaller compared to normal clinical setting. Moderate differences in drug
51
52 concentrations do not necessarily affect the pharmacologic response because of the log-linear relationship
53
54 between the drug concentration and effect. Furthermore, the power of this study was insufficient to show
55
56 differences between ritonavir or lopinavir/ritonavir and placebo phases in pharmacodynamic parameters,
57
58 because our primary interest was a change in the oxycodone AUC and the calculation of the sample size was
59
60 based on that endpoint.

1
2
3
4
5 The possibility of drug-drug interactions must be considered in the treatment of HIV-associated pain. In
6 previous pharmacokinetic studies in healthy volunteers, for instance, the oral bioavailability of alfentanil was
7 increased from 37% to 95% by steady-state ritonavir concentrations [18]. The acute administration of
8 ritonavir reduced the clearance of intravenous fentanyl by 67% [16]. In HIV-negative subjects receiving
9 buprenorphine/naloxone as opioid-replacement therapy, tipranavir/ritonavir reduced the formation of
10 CYP3A4 dependent active metabolite norbuprenorphine, but the AUC of parent drug remained unchanged
11 and no clinical opioid withdrawal symptoms were noted [47]. Contrary to the above mentioned studies, the
12 concentrations of methadone have been decreased after ritonavir probably due to the induction of CYP2B6
13 [43]. Thus, the effect of ritonavir on important opioids can be opposite. Drug-drug interactions in HIV-
14 associated pain management are not restricted only to opioids; concomitant administration of
15
16 lopinavir/ritonavir caused a 46% reduction in the plasma concentrations of lamotrigine, which is an
17
18 antiepileptic recommended as second or third line drug for the treatment of neuropathic pain [6]. The
19
20 mechanism behind this interaction might be the induction in lamotrigine glucuronidation [48]. Theoretically,
21
22 the induction of glucuronidation could have an influence on the metabolism of oxycodone and its
23
24 metabolites, but these metabolic routes are of minor importance [49] and they were not investigated in this
25
26 study. Additionally, it is unlikely, that short duration of ritonavir would have induced the glucuronidation of
27
28 noroxycodone and oxymorphone significantly.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44 In conclusion, administration of lopinavir/ritonavir and ritonavir greatly increases plasma concentrations of
45
46 oxycodone. Clinically, attention should be drawn to the concomitant use of oxycodone and ritonavir or
47
48 lopinavir/ritonavir and oxycodone. Further studies are needed to extend the results to HIV or AIDS pain
49
50 patients suffering from chronic pain.

51
52
53
54
55
56
57 The authors declare no conflicts of interest.
58
59
60

1
2
3 This study was supported by Turku University Hospital research fund EVO 13821 and Turku University
4
5 Foundation, Turku, Finland; Sigrid Jusélius Foundation and Instrumentarium Research Foundation, Helsinki,
6
7 Finland.
8

9
10 **Acknowledgements:** We want to thank Mrs. Elina Kahra, Medical laboratory technologist, and Mrs. Mia
11
12 Suppanen-Olkkola, RN, for their skilful technical assistance; Dr. Juha Grönlund, M.D., for his practical help
13
14 during the data collection and Mrs. Kaisa J. Kurkinen, M.Sc., for the determination of ritonavir and lopinavir
15
16 concentrations.
17

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

References

1. Lee KA, Gay C, Portillo CJ, Coggins T, Davis H, Pullinger CR, Aouizerat BE (2009) Symptom experience in HIV-infected adults: a function of demographic and clinical characteristics. *J Pain Symptom Manage* 38:882-893
2. Frich LM, Borgbjerg FM (2000) Pain and pain treatment in AIDS patients: a longitudinal study. *J Pain Symptom Manage* 19:339-347
3. Gray G, Berger P (2007) Pain in women with HIV/AIDS. *Pain* 132 Suppl 1:S13-21
4. Verma S, Estanislao L, Simpson D (2005) HIV-associated neuropathic pain: epidemiology, pathophysiology and management. *CNS Drugs* 19:325-334
5. Walker UA, Tyndall A, Daikeler T (2008) Rheumatic conditions in human immunodeficiency virus infection. *Rheumatology (Oxford)* 47:952-959
6. Freynhagen R, Bennett MI (2009) Diagnosis and management of neuropathic pain. *BMJ* 339:b3002
7. Kalso E (2005) Oxycodone. *J Pain Symptom Manage* 29:S47-56
8. Pöyhiä R, Seppälä T, Olkkola KT, Kalso E (1992) The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. *Br J Clin Pharmacol* 33:617-621
9. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD (2004) Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. *Drug Metab Dispos* 32:447-454
10. Boström E, Simonsson US, Hammarlund-Udenaes M (2005) Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833. *J Pharm Sci* 94:1060-1066
11. Hassan HE, Myers AL, Lee IJ, Coop A, Eddington ND (2007) Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. *J Pharm Sci* 96:2494-2506
12. Boström E, Simonsson US, Hammarlund-Udenaes M (2006) In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. *Drug Metab Dispos* 34:1624-1631
13. Villesen HH, Foster DJ, Upton RN, Somogyi AA, Martinez A, Grant C (2006) Cerebral kinetics of oxycodone in conscious sheep. *J Pharm Sci* 95:1666-1676
14. Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T, Deguchi Y (2008) Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. *Drug Metab Dispos* 36:2005-2013
15. Debouck C (1992) The HIV-1 protease as a therapeutic target for AIDS. *AIDS Res Hum Retroviruses* 8:153-164

16. Olkkola KT, Palkama VJ, Neuvonen PJ (1999) Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. *Anesthesiology* 91:681-685
17. Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, Touw DJ, Wieling J, Hekster YA, Burger DM (2005) Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. *Clin Pharmacol Ther* 78:664-674
18. Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C (2008) Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. *Clin Pharmacol Ther* 84:506-512
19. Liu P, Foster G, Gandelman K, LaBadie RR, Allison MJ, Gutierrez MJ, Sharma A (2007) Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. *Antimicrob Agents Chemother* 51:3617-3626
20. Kharasch ED, Mitchell D, Coles R, Blanco R (2008) Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. *Antimicrob Agents Chemother* 52:1663-1669
21. Hsu A, Granneman GR, Bertz RJ (1998) Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. *Clin Pharmacokinet* 35:275-291
22. Cvetkovic RS, Goa KL (2003) Lopinavir/ritonavir: a review of its use in the management of HIV infection. *Drugs* 63:769-802
23. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ, Jr, Klein CE, Rublein JC, Kashuba AD (2006) Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. *J Acquir Immune Defic Syndr* 42:52-60
24. Wyen C, Fuhr U, Frank D, Aarnoutse RE, Klaassen T, Lazar A, Seeringer A, Doroshenko O, Kirchheiner JC, Abdulrazik F, Schmeisser N, Lehmann C, Hein W, Schomig E, Burger DM, Fatkenheuer G, Jetter A (2008) Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. *Clin Pharmacol Ther* 84:75-82
25. Hagelberg NM, Nieminen TH, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Olkkola KT (2009) Voriconazole drastically increases exposure to oral oxycodone. *Eur J Clin Pharmacol* 65:263-271
26. Saari TI, Grönlund J, Hagelberg NM, Neuvonen M, Laine K, Neuvonen PJ, Olkkola KT (2010) Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. *Eur J Clin Pharmacol* 66:387-397
27. Grönlund J, Saari T, Hagelberg N, Martikainen IK, Neuvonen PJ, Olkkola KT, Laine K (2010) Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. *J Clin Pharmacol* 50:101-108
28. Michna E, Ross EL, Hynes WL, Nedeljkovic SS, Soumekh S, Janfaza D, Palombi D, Jamison RN (2004) Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. *J Pain Symptom Manage* 28:250-258
29. Sistonen J, Fuselli S, Levo A, Sajantila A (2005) CYP2D6 genotyping by a multiplex primer extension reaction. *Clin Chem* 51:1291-1295

- 1
2
3 30. Neuvonen M, Neuvonen PJ (2008) Determination of oxycodone, noroxycodone, oxymorphone, and
4 noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry.
5 *Ther Drug Monit* 30:333-340
6
- 7
8 31. Rezk NL, White NR, Jennings SH, Kashuba AD (2009) A novel LC-ESI-MS method for the
9 simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma. *Talanta*
10 79:1372-1378
11
- 12 32. Nieminen TH, Hagelberg NM, Saari TI, Pertovaara A, Neuvonen M, Laine K, Neuvonen PJ, Olkkola KT
13 (2009) Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
14 *Anesthesiology* 110:1371-1378
15
- 16 33. Bond AJ, Lader MH (1974) The use of analogue scales in rating subjective feelings. *Br J Med Psychol*
17 47:211-218
18
- 19 34. Hannington-Kiff JG (1970) Measurement of recovery from outpatient general anaesthesia with a simple
20 ocular test. *Br Med J* 3:132-135
21
- 22 35. Stone BM (1984) Pencil and paper tests-sensitivity to psychotropic drugs. *Br J Clin Pharmacol* 18:15S-
23 20S
24
- 25 36. Cogan DG (1941) Simplified entoptic pupillometer. *Am J Ophthalmol* 24:1431-1433
26
- 27 37. Jones SF, McQuay HJ, Moore RA, Hand CW (1988) Morphine and ibuprofen compared using the cold
28 pressor test. *Pain* 34:117-122
29
- 30 38. Ernest CS, 2nd, Hall SD, Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease
31 inhibitors. *J Pharmacol Exp Ther* 312:583-591
32
- 33 39. Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT (2006) Differential inhibition
34 of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease
35 inhibitors in vitro. *Basic Clin Pharmacol Toxicol* 98:79-85
36
- 37 40. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL,
38 Shader RI (2000) Alprazolam-ritonavir interaction: implications for product labeling. *Clin Pharmacol*
39 *Ther* 67:335-341
40
- 41 41. Ouellet D, Hsu A, Granneman GR, Carlson G, Cavanaugh J, Guenther H, Leonard JM (1998)
42 Pharmacokinetic interaction between ritonavir and clarithromycin. *Clin Pharmacol Ther* 64:355-362
43
- 44 42. Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, Valdes J, Smith J, Erdman K, Lyons N,
45 Niu P, Decourt JP, Fourtillan JB, Girault J, Leonard JM (1997) Multiple-dose pharmacokinetics of
46 ritonavir in human immunodeficiency virus-infected subjects. *Antimicrob Agents Chemother* 41:898-
47 905
48
- 49 43. Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS (2009) Methadone pharmacokinetics are
50 independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from
51 methadone interactions with ritonavir/indinavir. *Anesthesiology* 110:660-672
52
- 53 44. Weemhoff JL, von Moltke LL, Richert C, Hesse LM, Harmatz JS, Greenblatt DJ (2003) Apparent
54 mechanism-based inhibition of human CYP3A in-vitro by lopinavir. *J Pharm Pharmacol* 55:381-386
55
- 56 45. Kumar GN, Rodrigues AD, Buko AM, Denissen JF (1996) Cytochrome P450-mediated metabolism of
57 the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. *J Pharmacol Exp Ther*
58 277:423-431
59
60

- 1
2
3 46. Zwisler ST, Enggaard TP, Mikkelsen S, Brosen K, Sindrup SH (2010) Impact of the CYP2D6 genotype
4 on post-operative intravenous oxycodone analgesia. *Acta Anaesthesiol Scand* 54:232-240
5
6
7 47. Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C,
8 Andrews L, Friedland GH (2009) Pharmacokinetic interactions between buprenorphine/naloxone and
9 tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. *Drug*
10 *Alcohol Depend* 105:234-239
11
12 48. van der Lee MJ, Dawood L, ter Hofstede HJ, de Graaff-Teulen MJ, van Ewijk-Beneken Kolmer EW,
13 Caliskan-Yassen N, Koopmans PP, Burger DM (2006) Lopinavir/ritonavir reduces lamotrigine plasma
14 concentrations in healthy subjects. *Clin Pharmacol Ther* 80:159-168
15
16 49. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD (2006) Pharmacokinetics and
17 pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
18 *Clin Pharmacol Ther* 79:461-479
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir

Authors: Tuija H Nieminen, M.D.¹, Nora M Hagelberg, M.D., Ph.D.¹, Teijo I Saari, M.D., Ph.D.¹, Mikko Neuvonen, M.Sc.², Pertti J Neuvonen, M.D., Ph.D.², Kari Laine, M.D., Ph.D.³ Klaus T Olkkola, M.D., Ph.D.¹

Affiliations:

¹Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University Hospital and University of Turku, Turku, Finland.

²Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.

³Department of Pharmacology, Drug Development & Therapeutics, University of Turku, Turku, Finland.

Corresponding author:

Tuija H Nieminen, Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University Hospital, P.O. Box 52 (Kiinamylynkatu 4–8), FI–20521 Turku, Finland;
Tel. +358-2-313 0000 (work); Fax +358-2-313 3960 E-mail: tuija.nieminen@utu.fi

ABSTRACT

Purpose: This study was aimed to investigate the effect of antivirals ritonavir and lopinavir/ritonavir on the pharmacokinetics and pharmacodynamics of oral oxycodone, a widely used opioid receptor agonist used in the treatment of moderate to severe pain.

Methods: A randomized crossover study design with 3 phases at intervals of 4 weeks was conducted in 12 healthy volunteers. Ritonavir 300 mg, lopinavir/ritonavir 400/100 mg or placebo b.i.d. for 4 days was given to the subjects. On day 3, 10 mg oxycodone hydrochloride was administered orally. Plasma concentrations of oxycodone, noroxycodone, oxymorphone and noroxymorphone were determined for 48 h. Pharmacokinetic parameters were calculated with standard noncompartmental methods. Behavioural effects and experimental cold pain analgesia were assessed for 12 h. ANOVA for repeated measures was used for statistical analysis.

Results: Ritonavir and lopinavir/ritonavir increased the area under the plasma concentration–time curve of oral oxycodone by 3.0- (range 1.9- to 4.3-fold; $P<0.001$) and 2.6-fold (range 1.9- to 3.3-fold; $P<0.001$). The mean (\pm SD) elimination half-life prolonged after ritonavir and lopinavir/ritonavir from 3.6 ± 0.6 to 5.6 ± 0.9 h ($P<0.001$) and 5.7 ± 0.9 h ($P<0.001$), respectively. Both ritonavir ($P<0.001$) and lopinavir/ritonavir ($P<0.05$) increased the self-reported drug effect of oxycodone.

Conclusions: Ritonavir and lopinavir/ritonavir greatly increase the plasma concentrations of oral oxycodone in healthy volunteers and enhance its effect. When oxycodone is used clinically in patients during ritonavir and lopinavir/ritonavir treatment, reductions in oxycodone dose may be needed to avoid opioid-related adverse-effects.

Keywords: Oxycodone, Ritonavir, Lopinavir/ritonavir, Interaction, Pharmacokinetics, Pharmacodynamics

INTRODUCTION

Pain is one of the most frequently reported symptoms associated with human immunodeficiency virus (HIV) infection. It has been estimated that in the developed world, depending on the stage of disease and study settings, 30–80% of people living with HIV/AIDS are affected with pain [1, 2]. Pain experienced by HIV patients can be acute or chronic, and it is usually multifactorial in origin. HIV-associated pain can be due to e.g. HIV itself, antiretroviral treatment, opportunistic infections, HIV-associated cancers, rheumatic conditions or peripheral polyneuropathy [3-5]. Unfortunately, these painful conditions are often under-recognised and -treated.

Oxycodone is a semi-synthetic opioid agonist, which is effective in treating acute, cancer-related and chronic pain [6, 7]. It is metabolized mainly via oxidative, but also via reductive pathways with only 10–14% being excreted in unchanged or conjugated forms in urine [8]. Oxycodone is principally a cytochrome P450 3A4/5 substrate, which makes it prone to the interactions with CYP3A inducers and inhibitors [9]. The main oxidative pathway includes N-demethylation to noroxycodone by CYP3A4/5 and further to noroxymorphone by CYP2D6 [9]. Approximately 11% of oxycodone is O-demethylated to oxymorphone by CYP2D6, which is further transformed to noroxymorphone by CYP3A4/5 and CYP2D6 [9]. Animal studies have given controversial results about the role of P-glycoprotein in the transport of oxycodone via blood-brain barrier (BBB) [10, 11]. However, the higher concentrations of oxycodone in rat and sheep brain tissue compared to plasma concentrations suggest that the influx protein is much more active than P-glycoprotein, which acts as an efflux protein limiting the concentrations of oxycodone in brain [12-14].

HIV protease inhibitors, such as ritonavir and lopinavir inflict the HIV-specific aspartic protease enzyme on processing the *gag* and *gag-pol* polyprotein precursor, which leads to the production of immature, non-infectious viral particles [15]. Ritonavir is a potent CYP3A, CYP2D6 and P-glycoprotein inhibitor [16-18]. It has been described to induce CYP1A2, CYP2B6, CYP2C9 and CYP2C19 [19, 20]. Difficult dosing regimens, the development of resistance and adverse effects have restricted the use of ritonavir as an independent part of HIV treatment [21]. Lopinavir/ritonavir is a combination preparation, where lopinavir is

1
2
3 combined with low-dose ritonavir to enhance its low bioavailability by favourable CYP3A inhibition [22].

4
5 Lopinavir/ritonavir has become a well-tolerated, effective and preferred protease inhibitor in the treatment of
6
7 HIV. It is a substrate and inhibitor of CYP3A4 and to a lesser extent CYP2D6, and an inducer of CYP1A2,
8
9 2B6, 2C9 and 2C19 [23, 24] which makes it prone to cytochrome P450-mediated interactions.
10
11

12
13
14 In previous studies it has been shown, that CYP3A inhibitors voriconazole [25], itraconazole [26] and
15
16 telithromycin [27] increased the concentrations of oxycodone and oxymorphone, but only minor changes
17
18 have been observed in the pharmacological action of oxycodone following single doses in healthy
19
20 volunteers. As HIV patients are often affected with moderate to severe pain, there is an obvious need for the
21
22 concomitant use of antivirals and strong opioids, such as oxycodone. The aim of this study was to investigate
23
24 the effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics and effects of oxycodone in healthy
25
26 volunteers.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Participants

The study protocol was approved by the Ethics Committee of the Hospital District of Southwest Finland and by the Finnish National Agency for Medicines and was and was thereby reported to the EudraCT clinical trial register. In view of our previous studies, it was calculated, that 10 subjects would be required to detect a 30% difference in the area under the oxycodone concentration–time curves ($AUC_{0-\infty}$) at a level of significance $P = 0.05$ and power of 80% [25-27]. To allow a drop-out rate of 20%, we decided to recruit 12 subjects. Twelve healthy volunteers, four women and eight men (age 18–26 years; weight 52–84 kg) were studied according to the revised Declaration of Helsinki. Informed consent was obtained from all subjects before study screening. All participants were ascertained to be healthy by means of medical history and clinical examination, and they were tested for routine laboratory tests. Urine screens for drugs with abuse risk were negative and a 12–lead electrocardiogram (ECG) within normal limits. Pregnancy tests for women were negative. None of the participants were receiving any continuous medication including hormonal contraception and all were non-smokers. Women in need of contraception were instructed to use non-hormonal methods during the study.

Finnish translation of Abuse Questions [28] was used to assess risk for drug abuse. The consumption of any product with potential CYP3A effect such as herbal remedies or grapefruit juice was forbidden for 4 weeks and all other drugs for 2 weeks before and during the study. Consumption of coffee, tee, alcohol and cola drinks were not allowed in the study facility during the study days. Genotyping for CYP2D6 was conducted by a two-step multiplex primer extension method [29]. This method enables the detection of 11 most relevant polymorphic positions, the definition of whole-gene deletion, duplication and the allele combination in case of gene duplication.

Study design and drug dosing

1
2
3 We used a randomized, crossover study design with three phases at intervals of four weeks. During each
4
5 phase, the volunteers were given 4 capsules or tablets b.i.d. at 7 a.m. and 7 p.m. for 4 days. The capsules and
6
7 tablets were packed into sealed coded envelopes which contained either:
8

- 9
10 1. Two lopinavir/ritonavir 200 mg/50 mg tablets (Kaletra[®], Abbott Laboratories Ltd, Queenborough,
11
12 UK) and two placebo capsules
- 13
14 2. Three ritonavir 100 mg capsules (Norvir[®], Abbott Laboratories Ltd, Queenborough, UK) and one
15
16 placebo capsule
- 17
18 3. Four placebo capsules.

19
20 An oral dose of 10 mg oxycodone hydrochloride (Oxynorm[®] 10 mg capsule, Mundipharma, Bard
21
22 Pharmaceuticals Ltd, Cambridge, UK) was administered on day 3 at 8 a.m. with 150 ml warm water. The
23
24 participants arrived at the study facility one hour before oxycodone administration and were under
25
26 supervision 12 hours after the dosing.
27
28

29
30 The volunteers fasted for 8 h before oxycodone hydrochloride administration and received a standard meal 4
31
32 and 8 h after dosing. Drinking was allowed only during the meals. Adherence to the pre-treatment
33
34 medication schedule was ensured with mobile phone text messages, which the volunteers sent to the
35
36 investigator after taking each dose of pre-treatment taken outside the study facility.
37
38

39 40 41 **Sampling and determination of drug concentrations**

42
43 In the study facility, a cubital vein was cannulated for blood sampling. The samples (10 ml each) were
44
45 collected into EDTA containing tubes before and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 h after the oxycodone
46
47 hydrochloride dose. Plasma was separated within 30 min and stored at -70°C until analysis.
48
49

50
51
52 Plasma concentrations of oxycodone, noroxycodone, oxymorphone and noroxymorphone were analyzed
53
54 with the liquid chromatography–tandem mass spectrometric (LC–MS/MS) method as described earlier [30].
55
56 The lower limits of quantification (LLQ) were 0.1 ng/mL for oxycodone and oxymorphone, and 0.25 ng/mL
57
58 for noroxycodone and noroxymorphone. The interday coefficient of variation was less than 6% for parent
59
60 oxycodone and less than 13% for the metabolites at relevant plasma concentrations.

1
2
3
4
5 The concentrations of ritonavir and lopinavir just before and 2 h after the administration of the dose of
6 pretreatment on the day 3 were determined with a LC–MS/MS method [31]. Saquinavir was used as internal
7 standard. The LLQ was 0.1 µg/ml for ritonavir and 0.4 µg/ml for lopinavir. The interday CVs were < 5.4%
8 and < 7.0% for ritonavir and lopinavir, respectively, at relevant concentrations (n=3).
9
10
11
12
13

16 **Pharmacokinetic analysis**

17
18 The pharmacokinetics of oxycodone and its metabolites were determined by standard noncompartmental
19 methods using a pharmacokinetic program WinNonlin (version 4.1, Pharsight Corporation, Mountain View,
20 CA, USA). The peak plasma concentrations (C_{\max}) and the corresponding C_{\max} times (t_{\max}) were observed
21 directly from the data. The elimination rate constant (k_e) was determined by log-linear regression. The
22 elimination half-life $t_{1/2}$ was calculated from $\ln 2/k_e$. The areas under the oxycodone, noroxycodone,
23 oxymorphone and noroxymorphone concentration–time curves ($AUC_{0-\infty}$) were calculated by trapezoidal rule
24 with extrapolation to infinity. Whenever k_e could not be estimated because of low plasma concentrations of
25 the metabolite, AUC_{0-48} was used instead of $AUC_{0-\infty}$. The metabolite-to-parent drug AUC ratios
26 (AUC_m/AUC_p) were calculated to compare the relative abundance of each metabolite.
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Analysis of pharmacological effects**

44 ***Behavioral effects***

45
46 The behavioural measures were performed before and at 1, 2, 3, 4, 5, 6, 8, 10 and 12 h after oxycodone as
47 described earlier [32]. Subjective assessment of drowsiness, deterioration of performance, self-reported drug-
48 effect, pleasantness and nausea or vomiting was quantified using visual analog scales (VAS) and scored 0–
49 100. Attributes assessed included alert/drowsy, good/poor performance, no/strong drug effect,
50 unpleasant/pleasant feeling and no/extreme nausea or vomiting [33]. Maddox wing test was used to estimate
51 the central coordination of extraocular muscles [34]; digit symbol substitution test (DSST) to estimate the
52 central processing of sensory information [35] and Cogan's pupillometry to measure pupil diameter [36]. All
53 reported and observed adverse effects were recorded.
54
55
56
57
58
59
60

Experimental pain

The analgesic effect was studied in an experimental cold pressor test, which is sensitive to opioid effects [37]. The subjects placed their left hand up to the wrist into the ice water bath (temperature 0–2°C) for one minute and reported the first sensation of pain (cold pain threshold, CPT), which was measured in seconds with a stopwatch. The intensity of cold pain at 60 s (CPI) was assessed using numerical rating scale (NRS 0–100). The area under the drug effect–time curve (AUEC_{0–12}) from 0 to 12 hours was calculated with linear trapezoidal rule based on the observations by the use of the WinNonlin (version 4.1, Pharsight Corporation, Mountain View, CA, USA) software for all effect variables.

Statistics

The results are expressed as mean \pm SD, except for t_{\max} , where medians with minimum and maximum values are reported. In figures, for clarity, mean \pm SEM are given. Descriptive and comparative statistics were calculated with use of SYSTAT for Windows (version 10.2; Systat software, Richmond, CA, USA). The pharmacokinetic and pharmacodynamic variables were compared with the use of analysis of variance for repeated measures and a posteriori testing was performed with Tukey's test. Pharmacokinetic data was logarithmically transformed before statistical comparisons. Analysis of variance was used to determine the contributions of treatment, CYP2D6-genotype, gender, phase and sequence on overall variance. The t_{\max} was analyzed by Friedman's test and Wilcoxon signed rank test was used for pair wise comparisons. *P* was considered significant at the level of <0.05 . We also calculated geometric mean ratios with 90% confidence intervals (CI) for the pharmacokinetic parameters. Bioequivalence (i.e., the lack of an interaction) was concluded, if the 90% CI of the geometric mean ratios (coadministration/oxycodone alone) were within the acceptance limit of 0.8 to 1.25.

RESULTS

All subjects completed the study.

Pharmacokinetic results

The pharmacokinetic results are presented in Figure 1 and Table 1. During the ritonavir and lopinavir phases, all of the calculated pharmacokinetic parameters for oxycodone were outside the bioequivalence acceptance limits (Table 1). Compared with placebo, ritonavir and lopinavir/ritonavir increased the oxycodone $AUC_{0-\infty}$ (geometric mean ratio) by 3.0-fold (90% CI 2.6, 3.4; $P<0.001$) and 2.6-fold (90% CI 2.3, 2.9; $P<0.001$), respectively. Ritonavir increased the geometric mean ratio of oxycodone C_{max} by 1.7-fold (90% CI 1.5, 2.0; $P<0.001$) and prolonged its elimination half-life from 3.6 ± 0.6 h to 5.6 ± 0.9 h ($P<0.001$).

Lopinavir/ritonavir increased the geometric mean ratio of oxycodone C_{max} by 1.4-fold (90% CI 1.2, 1.7; $P<0.05$) and prolonged its elimination half-life to 5.7 ± 0.9 hours ($P<0.001$). Gender had no significant influence on the pharmacokinetic parameters of oxycodone.

Both ritonavir and lopinavir/ritonavir decreased the geometric mean ratio for noroxycodone AUC_{0-48} to 0.49 (90%CI 0.43, 0.58, $P<0.001$) and 0.44 (90%CI 0.38, 0.50; $P<0.001$), respectively. Ritonavir alone had no effect on oxymorphone but lopinavir/ritonavir increased geometric mean ratio for oxymorphone AUC_{0-48} by 2.7-fold (90%CI 2.0, 3.8; $P<0.05$). The geometric mean ratio for noroxymorphone AUC_{0-48} was 0.19 (90%CI 0.15, 0.24; $P<0.01$) after ritonavir and 0.24 (90%CI 0.16, 0.35; $P<0.01$) after lopinavir/ritonavir, respectively. Four subjects during ritonavir phase and three subjects during lopinavir/ritonavir phase had no detectable concentrations of noroxymorphone during the study period 0–48 hours.

Nine volunteers were classified as extensive metabolizers (EM). Three of them were homozygous for CYP2D6*1 allele and the rest of the genotypes were CYP2D6*1/4 ($n = 3$), CYP2D6*1/5 ($n = 2$) and CYP2D6*1/41 ($n=1$). Furthermore, there were two subjects with CYP2D6*1/1 x 2 genotype classified as ultrarapid metabolizer (UM) and one CYP2D6*10/*41 classified as intermediate metabolizer (IM). The IMs

1
2
3 appeared to have lower oxymorphone AUC values than most of the extensive metabolizers during all phases
4
5 (data not shown).
6
7
8

9
10 After pre-treatment with ritonavir, plasma ritonavir concentrations (mean \pm SD) measured $\frac{1}{2}$ and 3 hours
11 after the morning dose on day 3, were 3.2 ± 1.6 $\mu\text{g/ml}$ and 8.7 ± 2.6 $\mu\text{g/ml}$. After lopinavir/ritonavir pre-
12 treatment, the corresponding plasma lopinavir concentrations were 9.0 ± 2.0 $\mu\text{g/ml}$ and 11.3 ± 2.9 $\mu\text{g/ml}$ and
13 ritonavir concentrations 0.5 ± 0.3 $\mu\text{g/ml}$ and 1.0 ± 0.5 $\mu\text{g/ml}$, respectively. All volunteers had measurable
14
15
16
17
18 values of ritonavir and ritonavir/lopinavir before the morning dose during active phases indicating
19
20 compliance to the dosing schedule.
21
22
23
24

25 **Pharmacodynamic results**

26
27 Results from behavioral and analgesic tests are shown in Fig. 2. The self-reported drug effect AUEC_{0-12}
28 increased significantly after ritonavir and lopinavir/ritonavir ($P < 0.001$ and < 0.05). Ritonavir increased also
29 nausea or vomiting as measured by VAS ($P < 0.01$), but no other statistically significant differences were
30
31
32
33 observed in the pharmacological response to oxycodone.
34
35
36
37

38 The adverse effects reported are presented in Table 2. All three volunteers with vomiting were treated with 2
39
40 mg intravenous tropisetron 4, 8 or 12 h after oxycodone.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

This study convincingly demonstrates that short-term administration of ritonavir and lopinavir/ritonavir strongly inhibits the CYP3A-mediated N-demethylation of oxycodone, as reflected by an approximately 2–3-fold increase in oxycodone $AUC_{0-\infty}$ and decrease in noroxycodone AUC_{0-48} . When oxycodone was administered together with ritonavir or lopinavir/ritonavir, the mean concentration of oxycodone was still higher at 8 h than the C_{max} during the control phase. These pharmacokinetic changes were accompanied by enhanced self-reported drug-effect after both antiviral treatments.

Ritonavir has been shown to be a strong inhibitor of CYP3A both *in vitro* [38, 39] and *in vivo* [16, 18, 40, 41]. In the present study ritonavir caused a 3-fold mean increase of oxycodone $AUC_{0-\infty}$, which is somewhat smaller than that observed after the azole antimycotic voriconazole (3.6-fold increase in oxycodone $AUC_{0-\infty}$), but bigger than that observed for itraconazole (2.4-fold increase) and telithromycin (1.8-fold increase) [25-27]. It can be speculated, although it seems doubtful, that the interaction between oxycodone and ritonavir would have been stronger, if a larger ritonavir dose would have been used as recommended by the manufacturer. However, because we wanted to minimize possible adverse effects in healthy volunteers, 300 mg b.i.d. was used and the treatment lasted only four days. This could lead to bias, as the steady-state was not reached [21]. Ritonavir has been reported to cause an enzyme induction after approximately 2 weeks administration, which can diminish the inhibitory effects [42, 43].

Interestingly, lopinavir/ritonavir resulted in an almost equal alteration in oxycodone pharmacokinetics as compared to ritonavir. The clinically used maintenance dose of ritonavir is 600 mg b.i.d., which is recommended to be attained during 2 weeks to avoid adverse effects. During the 4-day pre-treatment our volunteers were given 300 mg of ritonavir b.i.d., which is three times higher than the dose of ritonavir during lopinavir/ritonavir phase. Still, the pharmacokinetics of oxycodone was very similar whether it was given together with ritonavir or lopinavir/ritonavir. A plausible explanation for the observed pharmacokinetic changes is the additional inhibitory effect by lopinavir. Lopinavir is a less potent inhibitor of CYP3A *in vitro* than ritonavir, but it might nonetheless contribute to net CYP3A inhibition *in vivo* during the treatment with

1
2
3 the combination of lopinavir and ritonavir. The dose-response curve for CYP3A inhibition by ritonavir can
4
5 be so flat *in vivo* that despite a 3-fold dose reduction, it causes a maximal inhibition of CYP3A when
6
7 combined with a 4-fold higher dose of lopinavir [44].
8
9

10
11 Ritonavir inhibits CYP2D6 *in vitro*, but to a lesser extent than it inhibits CYP3A [44, 45]. In the present
12
13 study, oxycodone concentrations were increased during both antiviral phases indicating the increased
14
15 significance of compensatory oxycodone metabolic route via CYP2D6 during CYP3A inhibition. In a
16
17 previous study, coadministration of oxycodone and telithromycin, an inhibitor of CYP3A and CYP2D6,
18
19 shifted the metabolism of oxycodone towards the CYP2D6-mediated route increasing oxycodone
20
21 concentrations [27]. After lopinavir/ritonavir, the geometric mean ratio for oxycodone AUC was
22
23 increased by 2.7-fold. Earlier studies have reported CYP2D6 inhibition during lopinavir/ritonavir [17, 24].
24
25 The inhibition was not strong enough to totally hinder the compensation via CYP2D6-mediated route after
26
27 CYP3A inhibition. The formation of oxycodone has recently been shown to be dependent on CYP2D6
28
29 genotype [46]. In our study with only 12 healthy volunteers, there were 9 extensive, one intermediate, two
30
31 ultrarapid but no poor metabolizers. In the present small-scale study these genotypes were not associated
32
33 with changes in pharmacokinetic parameters of oxycodone or its metabolites.
34
35
36
37
38
39

40 The self-reported drug effect of oxycodone was significantly increased by both ritonavir and
41
42 lopinavir/ritonavir. As well as oxycodone, also ritonavir was involved in the side-effects because
43
44 approximately 25% of ritonavir users typically report nausea or vomiting [21]. Contrary to our previous
45
46 studies, oxycodone reduced pain in the cold pressor test only in some subjects. As only a single dose of
47
48 oxycodone was used in the current study in order to minimize the exposure of healthy volunteers to opioids,
49
50 drug effect remained smaller compared to normal clinical setting. Moderate differences in drug
51
52 concentrations do not necessarily affect the pharmacologic response because of the log-linear relationship
53
54 between the drug concentration and effect. Furthermore, the power of this study was insufficient to show
55
56 differences between ritonavir or lopinavir/ritonavir and placebo phases in pharmacodynamic parameters,
57
58 because our primary interest was a change in the oxycodone AUC and the calculation of the sample size was
59
60 based on that endpoint.

1
2
3
4
5 The possibility of drug-drug interactions must be considered in the treatment of HIV-associated pain. In
6 previous pharmacokinetic studies in healthy volunteers, for instance, the oral bioavailability of alfentanil was
7 increased from 37% to 95% by steady-state ritonavir concentrations [18]. The acute administration of
8 ritonavir reduced the clearance of intravenous fentanyl by 67% [16]. In HIV-negative subjects receiving
9 buprenorphine/naloxone as opioid-replacement therapy, tipranavir/ritonavir reduced the formation of
10 CYP3A4 dependent active metabolite norbuprenorphine, but the AUC of parent drug remained unchanged
11 and no clinical opioid withdrawal symptoms were noted [47]. Contrary to the above mentioned studies, the
12 concentrations of methadone have been decreased after ritonavir probably due to the induction of CYP2B6
13 [43]. Thus, the effect of ritonavir on important opioids can be opposite. Drug-drug interactions in HIV-
14 associated pain management are not restricted only to opioids; concomitant administration of
15 lopinavir/ritonavir caused a 46% reduction in the plasma concentrations of lamotrigine, which is an
16 antiepileptic recommended as second or third line drug for the treatment of neuropathic pain [6]. The
17 mechanism behind this interaction might be the induction in lamotrigine glucuronidation [48]. Theoretically,
18 the induction of glucuronidation could have an influence on the metabolism of oxycodone and its
19 metabolites, but these metabolic routes are of minor importance [49] and they were not investigated in this
20 study. Additionally, it is unlikely, that short duration of ritonavir would have induced the glucuronidation of
21 noroxycodone and oxymorphone significantly.

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44 In conclusion, administration of lopinavir/ritonavir and ritonavir greatly increases plasma concentrations of
45 oxycodone. Clinically, attention should be drawn to the concomitant use of oxycodone and ritonavir or
46 lopinavir/ritonavir and oxycodone. Further studies are needed to extend the results to HIV or AIDS pain
47 patients suffering from chronic pain.
48
49
50

51
52
53
54
55
56
57 The authors declare no conflicts of interest.
58
59
60

1
2
3 This study was supported by Turku University Hospital research fund EVO 13821 and Turku University
4
5 Foundation, Turku, Finland; Sigrid Jusélius Foundation and Instrumentarium Research Foundation, Helsinki,
6
7 Finland.
8

9
10 **Acknowledgements:** We want to thank Mrs. Elina Kahra, Medical laboratory technologist, and Mrs. Mia
11
12 Suppanen-Olkkola, RN, for their skilful technical assistance; Dr. Juha Grönlund, M.D., for his practical help
13
14 during the data collection and Mrs. Kaisa J. Kurkinen, M.Sc., for the determination of ritonavir and lopinavir
15
16 concentrations.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

References

1. Lee KA, Gay C, Portillo CJ, Coggins T, Davis H, Pullinger CR, Aouizerat BE (2009) Symptom experience in HIV-infected adults: a function of demographic and clinical characteristics. *J Pain Symptom Manage* 38:882-893
2. Frich LM, Borgbjerg FM (2000) Pain and pain treatment in AIDS patients: a longitudinal study. *J Pain Symptom Manage* 19:339-347
3. Gray G, Berger P (2007) Pain in women with HIV/AIDS. *Pain* 132 Suppl 1:S13-21
4. Verma S, Estanislao L, Simpson D (2005) HIV-associated neuropathic pain: epidemiology, pathophysiology and management. *CNS Drugs* 19:325-334
5. Walker UA, Tyndall A, Daikeler T (2008) Rheumatic conditions in human immunodeficiency virus infection. *Rheumatology (Oxford)* 47:952-959
6. Freynhagen R, Bennett MI (2009) Diagnosis and management of neuropathic pain. *BMJ* 339:b3002
7. Kalso E (2005) Oxycodone. *J Pain Symptom Manage* 29:S47-56
8. Pöyhiä R, Seppälä T, Olkkola KT, Kalso E (1992) The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. *Br J Clin Pharmacol* 33:617-621
9. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD (2004) Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. *Drug Metab Dispos* 32:447-454
10. Boström E, Simonsson US, Hammarlund-Udenaes M (2005) Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833. *J Pharm Sci* 94:1060-1066
11. Hassan HE, Myers AL, Lee IJ, Coop A, Eddington ND (2007) Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. *J Pharm Sci* 96:2494-2506
12. Boström E, Simonsson US, Hammarlund-Udenaes M (2006) In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. *Drug Metab Dispos* 34:1624-1631
13. Villesen HH, Foster DJ, Upton RN, Somogyi AA, Martinez A, Grant C (2006) Cerebral kinetics of oxycodone in conscious sheep. *J Pharm Sci* 95:1666-1676
14. Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T, Deguchi Y (2008) Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. *Drug Metab Dispos* 36:2005-2013
15. Debouck C (1992) The HIV-1 protease as a therapeutic target for AIDS. *AIDS Res Hum Retroviruses* 8:153-164

16. Olkkola KT, Palkama VJ, Neuvonen PJ (1999) Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. *Anesthesiology* 91:681-685
17. Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, Touw DJ, Wieling J, Hekster YA, Burger DM (2005) Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. *Clin Pharmacol Ther* 78:664-674
18. Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C (2008) Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. *Clin Pharmacol Ther* 84:506-512
19. Liu P, Foster G, Gandelman K, LaBadie RR, Allison MJ, Gutierrez MJ, Sharma A (2007) Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. *Antimicrob Agents Chemother* 51:3617-3626
20. Kharasch ED, Mitchell D, Coles R, Blanco R (2008) Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. *Antimicrob Agents Chemother* 52:1663-1669
21. Hsu A, Granneman GR, Bertz RJ (1998) Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. *Clin Pharmacokinet* 35:275-291
22. Cvetkovic RS, Goa KL (2003) Lopinavir/ritonavir: a review of its use in the management of HIV infection. *Drugs* 63:769-802
23. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ, Jr, Klein CE, Rublein JC, Kashuba AD (2006) Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. *J Acquir Immune Defic Syndr* 42:52-60
24. Wyen C, Fuhr U, Frank D, Aarnoutse RE, Klaassen T, Lazar A, Seeringer A, Doroshenko O, Kirchheiner JC, Abdulrazik F, Schmeisser N, Lehmann C, Hein W, Schomig E, Burger DM, Fatkenheuer G, Jetter A (2008) Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. *Clin Pharmacol Ther* 84:75-82
25. Hagelberg NM, Nieminen TH, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Olkkola KT (2009) Voriconazole drastically increases exposure to oral oxycodone. *Eur J Clin Pharmacol* 65:263-271
26. Saari TI, Grönlund J, Hagelberg NM, Neuvonen M, Laine K, Neuvonen PJ, Olkkola KT (2010) Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. *Eur J Clin Pharmacol* 66:387-397
27. Grönlund J, Saari T, Hagelberg N, Martikainen IK, Neuvonen PJ, Olkkola KT, Laine K (2010) Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. *J Clin Pharmacol* 50:101-108
28. Michna E, Ross EL, Hynes WL, Nedeljkovic SS, Soumekh S, Janfaza D, Palombi D, Jamison RN (2004) Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. *J Pain Symptom Manage* 28:250-258
29. Sistonen J, Fuselli S, Levo A, Sajantila A (2005) CYP2D6 genotyping by a multiplex primer extension reaction. *Clin Chem* 51:1291-1295

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

30. Neuvonen M, Neuvonen PJ (2008) Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry. *Ther Drug Monit* 30:333-340
31. Rezk NL, White NR, Jennings SH, Kashuba AD (2009) A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma. *Talanta* 79:1372-1378
32. Nieminen TH, Hagelberg NM, Saari TI, Pertovaara A, Neuvonen M, Laine K, Neuvonen PJ, Olkkola KT (2009) Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. *Anesthesiology* 110:1371-1378
33. Bond AJ, Lader MH (1974) The use of analogue scales in rating subjective feelings. *Br J Med Psychol* 47:211-218
34. Hannington-Kiff JG (1970) Measurement of recovery from outpatient general anaesthesia with a simple ocular test. *Br Med J* 3:132-135
35. Stone BM (1984) Pencil and paper tests-sensitivity to psychotropic drugs. *Br J Clin Pharmacol* 18:15S-20S
36. Cogan DG (1941) Simplified entoptic pupillometer. *Am J Ophthalmol* 24:1431-1433
37. Jones SF, McQuay HJ, Moore RA, Hand CW (1988) Morphine and ibuprofen compared using the cold pressor test. *Pain* 34:117-122
38. Ernest CS, 2nd, Hall SD, Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. *J Pharmacol Exp Ther* 312:583-591
39. Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT (2006) Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. *Basic Clin Pharmacol Toxicol* 98:79-85
40. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI (2000) Alprazolam-ritonavir interaction: implications for product labeling. *Clin Pharmacol Ther* 67:335-341
41. Ouellet D, Hsu A, Granneman GR, Carlson G, Cavanaugh J, Guenther H, Leonard JM (1998) Pharmacokinetic interaction between ritonavir and clarithromycin. *Clin Pharmacol Ther* 64:355-362
42. Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, Valdes J, Smith J, Erdman K, Lyons N, Niu P, Decourt JP, Fourtillan JB, Girault J, Leonard JM (1997) Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. *Antimicrob Agents Chemother* 41:898-905
43. Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS (2009) Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. *Anesthesiology* 110:660-672
44. Weemhoff JL, von Moltke LL, Richert C, Hesse LM, Harmatz JS, Greenblatt DJ (2003) Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. *J Pharm Pharmacol* 55:381-386
45. Kumar GN, Rodrigues AD, Buko AM, Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. *J Pharmacol Exp Ther* 277:423-431

- 1
2
3 46. Zwisler ST, Enggaard TP, Mikkelsen S, Brosen K, Sindrup SH (2010) Impact of the CYP2D6 genotype
4 on post-operative intravenous oxycodone analgesia. *Acta Anaesthesiol Scand* 54:232-240
5
6 47. Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C,
7 Andrews L, Friedland GH (2009) Pharmacokinetic interactions between buprenorphine/naloxone and
8 tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. *Drug*
9 *Alcohol Depend* 105:234-239
10
11 48. van der Lee MJ, Dawood L, ter Hofstede HJ, de Graaff-Teulen MJ, van Ewijk-Beneken Kolmer EW,
12 Caliskan-Yassen N, Koopmans PP, Burger DM (2006) Lopinavir/ritonavir reduces lamotrigine plasma
13 concentrations in healthy subjects. *Clin Pharmacol Ther* 80:159-168
14
15 49. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD (2006) Pharmacokinetics and
16 pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
17 *Clin Pharmacol Ther* 79:461-479
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Pharmacokinetic parameters of oxycodone and its primary and secondary oxidative metabolites after oral administration of 10 mg of oxycodone hydrochloride following pre-treatment with placebo (control), oral ritonavir or lopinavir/ritonavir in 12 healthy volunteers.

Parameter	Control phase	Ritonavir phase [geometric mean ratio (90% CI)]	Lopinavir/ritonavir phase [geometric mean ratio (90% CI)]
Oxycodone			
C_{\max} (ng/ml)	20.2 ± 6.8	34.1 ± 7.3*** [1.74 (1.55–1.95)]	27.7 ± 7.2* [1.38 (1.17–1.66)]
t_{\max} (h)	1.5 (0.5–1.5)	1.5 (0.5–5.0)	2.5 (0.5–5.0)*
$AUC_{0-\infty}$ (µg·min/ml)	6.8 ± 2.3	19.6 ± 4.6*** [2.95 (2.57–3.39)]	17.3 ± 4.3*** [2.57 (2.34–2.88)]
$t_{1/2}$ (h)	3.6 ± 0.6	5.6 ± 0.9*** [1.55 (1.45–1.62)]	5.7 ± 0.9*** [1.58 (1.48–1.66)]
Noroxycodone			
AUC_{0-48} (µg·min/ml)	7.6 ± 2.1	3.8 ± 1.4*** [0.49 (0.43–0.58)]	3.4 ± 1.5*** [0.44 (0.38–0.50)]
Oxymorphone			
AUC_{0-48} (µg·min/ml)	2.19 ± 1.77	2.8 ± 2.42 [1.07 (0.60–1.90)]	5.0 ± 2.2* [2.69 (1.95–3.80)]
Noroxymorphone			
AUC_{0-48} (µg·min/ml)	1.65 ± 0.63	0.27 ± 0.26** [0.19 (0.15–0.24)]	0.03 ± 0.03** [0.24 (0.16–0.35)]

The results are given as mean ± SD and geometric mean ratio (90% CI), except for t_{\max} , which is given as mean and range.

Significantly different *(P<0.05), **(P<0.01) or ***(P<0.001) from the control phase.

C_{\max} = maximum concentration, t_{\max} = time to maximum concentration, $AUC_{0-\infty}$ = area under plasma concentration–time curve extrapolated to infinity, AUC_{0-48} = area under plasma concentration–time curve from zero to 48 hours, $t_{1/2}$ = elimination half-life.

Table 2. Adverse effects in 12 healthy volunteers after placebo, ritonavir and lopinavir/ritonavir pre-treatment and during test days, after placebo, ritonavir and lopinavir/ritonavir and oral oxycodone hydrochloride 10 mg.

Adverse effect	Pre-treatment			Test days		
	<i>Placebo</i>	<i>Ritonavir</i>	<i>Lopinavir/ ritonavir</i>	<i>Placebo</i>	<i>Ritonavir</i>	<i>Lopinavir/ ritonavir</i>
Dizziness	0	0	0	5	5	7
Itching	0	0	0	4	4	4
Tiredness	0	0	0	2	0	0
Diarrhoea	0	2	3	0	0	0
Abdominal Irritation	0	3	3	0	0	0
Nausea	0	0	3	4	4	2
Vomiting	0	0	0	2	2	1

(n=number of subjects)




Fig. 1. Plasma concentrations (mean \pm SEM) of oxycodone and its metabolites in 12 healthy volunteers after administration of placebo (control), ritonavir (RIT, 300 mg b.i.d.) or lopinavir/ritonavir (LPV/r, 400/100 mg b.i.d.) for four days. Oxycodone hydrochloride (10 mg per os) was given on day 3 at 8 a.m. with 150 ml of warm water. For clarity, SEMs were used instead of SDs. SEMs can be converted into SDs by multiplying it with square root of 12 (3.46). Time = 0 refers to the time of oxycodone administration.

178x115mm (600 x 600 DPI)




Fig. 2. Pharmacodynamic parameters in 12 healthy volunteers after administration of placebo (control), ritonavir (RIT, 300 mg b.i.d.) or lopinavir/ritonavir (LPV/r, 400/100 mg b.i.d.) for four days. Oxycodone hydrochloride (10 mg per os) was given on day 3 at 8 a.m. with 150 ml of warm water. The figures are presented as mean (\pm SEM) of self-reported drug effect and nausea (VAS 0–100), pupil size (mm), cold pain threshold (CPT in seconds,) value in Digit Symbol Substitution test (DSST) and value in co-ordination of the extraocular muscles (diopters) in 12 healthy volunteers. For clarity, SEMs were used instead of SDs. SEMs can be converted into SDs by multiplying it with square root of 12 (3.46). Time = 0 refers to the time of oxycodone administration.

178x80mm (600 x 600 DPI)

Review